Companies/HK/3347

Hangzhou Tigermed Consulting Co., Ltd · 泰格医药

Income flow

Annual
3347 10-K Income StatementPeriod 2025-12-31Source 10-K
Net salesHKD 7B+126433% Y/YRevenueHKD 7B+126433% Y/YGross profitHKD 2BCost of revenueHKD 5BOperating profitHKD 1B-100% Y/YOperating expensesHKD 770MNet profitHKD 920MTaxHKD 83MOperating expensesHKD 770M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.35%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.0.77%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0.126PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.117.3%Shares outTotal shares currently outstanding (issued and not retired).123.1MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).646.0M
Dividend calendar
Ex-dividend
2026-06-18
Last cash
0.1447 · 2026-06-18